Clin Exp Otorhinolaryngol.  2021 Feb;14(1):108-115. 10.21053/ceo.2019.01550.

Comprehensive Analysis of Clinicopathologic Factors Predictive of an Unfavorable Prognosis in Patients With Acinic Cell Carcinoma of the Parotid Gland

• Park YM
• Yoon SO
• Kim JH
• Kang MS
• Kim DH
• Koh YW
• Kim SH
• Lim JY
• Choi EC

• KMID: 2512889
• DOI: http://doi.org/10.21053/ceo.2019.01550

Abstract

Objectives
. In subset of patients, acinic cell carcinoma (AcCC) exhibits aggressive features such as recurrence, distant metastasis, and mortality. This study aimed to investigate clinicopathologic factors influencing patients’ prognosis and to identify adverse features predictive of an unfavorable prognosis.
Methods
. Between January 2000 and December 2016, 59 patients with AcCC were enrolled in this study.
Results
. The patients’ 5-year overall survival rate was 93.3%, and their 5-year recurrence-free survival rate was 80.5%. During the study period, recurrence occurred in 10 patients. The mean time to recurrence after surgery was 26 months (range, 5–60 months). During the study period, three patients died from the disease. Univariate analysis showed that sex, surgical extent, extranodal extension, T classification, and TNM stage were significantly associated with disease recurrence. Multivariate analysis showed that, among the clinicopathologic factors included in the analysis, only TNM stage displayed a statistically significant correlation with disease recurrence.
Conclusion
. Surgical treatment alone yielded good results for AcCC, and additional treatment did not affect the recurrence-free survival rate or the overall survival rate, even when the resection margin was less than 1 mm. Other pathologic factors did not show prognostic significance for disease recurrence or death.

Keyword

Acinic Cell Carcinoma; Parotid Gland; Prognostic Factor

Figure

• 

  Fig. 1. Five-year overall survival (A) and 5-year recurrence-free survival (B) among all patients.

• 

  Fig. 2. Disease recurrence and death events in patients with acinic cell carcinoma of the parotid gland after surgery. (A) Disease recurrence and death events. (B) Disease recurrence pattern.

• 

  Fig. 3. Kaplan-Meier analysis of 5-year recurrence-free survival according to sex (A), TNM stage (B), and T classification (C).

• 

  Fig. 4. Kaplan-Meier analysis of 5-year overall survival according to TNM stage (A) and T classification (B).

Reference

1. Patel NR, Sanghvi S, Khan MN, Husain Q, Baredes S, Eloy JA. Demographic trends and disease-specific survival in salivary acinic cell carcinoma: an analysis of 1129 cases. Laryngoscope. 2014; Jan. 124(1):172–8.

2. Gomez DR, Katabi N, Zhung J, Wolden SL, Zelefsky MJ, Kraus DH, et al. Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland. Cancer. 2009; May. 115(10):2128–37.

3. Biron VL, Lentsch EJ, Gerry DR, Bewley AF. Factors influencing survival in acinic cell carcinoma: a retrospective survival analysis of 2061 patients. Head Neck. 2015; Jun. 37(6):870–7.

4. Cho JK, Lim BW, Kim EH, Ko YH, Oh D, Noh JM, et al. Low-grade salivary gland cancers: treatment outcomes, extent of surgery and indications for postoperative adjuvant radiation therapy. Ann Surg Oncol. 2016; Dec. 23(13):4368–75.

5. Richter SM, Friedmann P, Mourad WF, Hu KS, Persky MS, Harrison LB. Postoperative radiation therapy for small, low-/intermediate-grade parotid tumors with close and/or positive surgical margins. Head Neck. 2012; Jul. 34(7):953–5.

6. Bakst RL, Su W, Ozbek U, Knoll MA, Miles BA, Gupta V, et al. Adjuvant radiation for salivary gland malignancies is associated with improved survival: a National Cancer Database analysis. Adv Radiat Oncol. 2017; Apr. 2(2):159–66.

7. Stodulski D, Mikaszewski B, Majewska H, Wisniewski P, Stankiewicz C. Close surgical margin after conservative parotidectomy in early stage low-/intermediate-grade parotid carcinoma: outcome of watch and wait policy. Oral Oncol. 2017; May. 68:1–4.

8. Hoffman HT, Karnell LH, Robinson RA, Pinkston JA, Menck HR. National Cancer Data Base report on cancer of the head and neck: acinic cell carcinoma. Head Neck. 1999; Jul. 21(4):297–309.

9. Vander Poorten V, Triantafyllou A, Thompson LD, Bishop J, Hauben E, Hunt J, et al. Salivary acinic cell carcinoma: reappraisal and update. Eur Arch Otorhinolaryngol. 2016; Nov. 273(11):3511–31.

10. Neskey DM, Klein JD, Hicks S, Garden AS, Bell DM, El-Naggar AK, et al. Prognostic factors associated with decreased survival in patients with acinic cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2013; Nov. 139(11):1195–202.

11. Andreoli MT, Andreoli SM, Shrime MG, Devaiah AK. Radiotherapy in parotid acinic cell carcinoma: does it have an impact on survival? Arch Otolaryngol Head Neck Surg. 2012; May. 138(5):463–6.

12. Cha W, Kim MS, Ahn JC, Cho SW, Sunwoo W, Song CM, et al. Clinical analysis of acinic cell carcinoma in parotid gland. Clin Exp Otorhinolaryngol. 2011; Dec. 4(4):188–92.